A Patient with Advanced Hepatocellular Carcinoma Treated with Sorafenib Tosylate Showed Massive Tumor Lysis with Avoidance of Tumor Lysis syndrome

被引：21

作者：

Joshita, Satoru ^{[1
]}

Yoshizawa, Kaname ^{[1
]}

Sano, Kenji ^{[2
]}

Kobayashi, Satoshi ^{[1
]}

Sekiguchi, Tomohiro ^{[3
]}

Morita, Susumu ^{[1
]}

Kamijo, Atsushi ^{[1
]}

Komatsu, Michiharu ^{[1
]}

Umemura, Takeji ^{[1
]}

Ichijo, Tetsuya ^{[1
]}

Matsumoto, Akihiro ^{[1
]}

Tanaka, Eiji ^{[1
]}

机构：

[1] Shinshu Univ, Sch Med, Dept Med, Div Gastroenterol & Hepatol, Matsumoto, Nagano 390, Japan

[2] Shinshu Univ Hosp, Dept Lab Med, Matsumoto, Nagano, Japan

[3] Shinshu Univ Hosp, Dept Clin Training Ctr, Matsumoto, Nagano, Japan

来源：

INTERNAL MEDICINE | 2010年 / 49卷 / 11期

关键词：

hepatocellular carcinoma; sorafenib; tumor lysis; tumor lysis syndrome; ENDOTHELIAL GROWTH-FACTOR; CELL CARCINOMA; ANGIOGENESIS; EXPRESSION; SUNITINIB;

D O I：

10.2169/internalmedicine.49.3153

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A 33-year-old man presented with pain and palsy of the leg in 2008 for treatment of hepatocellular carcinoma with huge distant metastases. The patient's tumors had slowly enlarged despite several treatments. Oral administration of sorafenib at 800 mg/day with careful observation was commenced in 2009. Laboratory investigations on day 7 showed massive tumor lysis. An abdominal CT showed multiple low density areas and tumor markers decreased, indicating extended tumor necrosis. In conclusion, clinicians should bear in mind not only the published adverse effects, but also massive tumor lysis, when treating patients with large tumor burden by sorafenib.

引用

页码：991 / 994

页数：4

共 12 条

[1] Tumour lysis syndrome: new therapeutic strategies and classification
Cairo, MS
Bishop, M
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2004, 127 (01) : 3 - 11
[2] Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient
Huang, Wu-Shiung
Yang, Chang-Hsu
[J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (35) : 4464 - 4466
[3] Tumor lysis syndrome in small cell carcinoma and other solid tumors
Kalemkerian, GP
Darwish, B
Varterasian, ML
[J]. AMERICAN JOURNAL OF MEDICINE, 1997, 103 (05) : 363 - 367
[4] Sorafenib in advanced hepatocellular carcinoma
Llovet, Josep M.
Ricci, Sergio
Mazzaferro, Vincenzo
Hilgard, Philip
Gane, Edward
Blanc, Jean-Frederic
Cosme de Oliveira, Andre
Santoro, Armando
Raoul, Jean-Luc
Forner, Alejandro
Schwartz, Myron
Porta, Camillo
Zeuzem, Stefan
Bolondi, Luigi
Greten, Tim F.
Galle, Peter R.
Seitz, Jean-Francois
Borbath, Ivan
Haussinger, Dieter
Giannaris, Tom
Shan, Minghua
Moscovici, Marius
Voliotis, Dimitris
Bruix, Jordi
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) : 378 - 390
[5] Michels J., 2009, Invest New Drugs
[6] Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate
Nicholaou, Theo
Wong, Rachel
Davis, Ian D.
[J]. LANCET, 2007, 369 (9577) : 1923 - 1924
[7] The management of tumor lysis syndrome
Rampello, Elvira
Fricia, Tiziana
Malaguarnera, Mariano
[J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (08): : 438 - 447
[8] Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib
Saylor, Philip J.
Reid, Tony R.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (23) : 3544 - 3546
[9] Angiogenesis and hepatocellular carcinoma
Semela, D
Dufour, JF
[J]. JOURNAL OF HEPATOLOGY, 2004, 41 (05) : 864 - 880
[10] BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
Wilhelm, SM
Carter, C
Tang, LY
Wilkie, D
McNabola, A
Rong, H
Chen, C
Zhang, XM
Vincent, P
McHugh, M
Cao, YC
Shujath, J
Gawlak, S
Eveleigh, D
Rowley, B
Liu, L
Adnane, L
Lynch, M
Auclair, D
Taylor, I
Gedrich, R
Voznesensky, A
Riedl, B
Post, LE
Bollag, G
Trail, PA
[J]. CANCER RESEARCH, 2004, 64 (19) : 7099 - 7109

← 1 2 →